Daily Endocrinology Research Analysis
Three high-impact studies in endocrinology and metabolism stood out today: a large randomized trial (GRADE) found no cognitive differences among second-line glucose-lowering drug classes added to metformin, but worse glycemic control modestly correlated with poorer cognition. A HAPO follow-up analysis showed additive risk of impaired glucose tolerance in youth from maternal hyperglycemia and a high type 2 diabetes genetic risk score. A nationwide Korean cohort linked the triglyceride-glucose ind
Summary
Three high-impact studies in endocrinology and metabolism stood out today: a large randomized trial (GRADE) found no cognitive differences among second-line glucose-lowering drug classes added to metformin, but worse glycemic control modestly correlated with poorer cognition. A HAPO follow-up analysis showed additive risk of impaired glucose tolerance in youth from maternal hyperglycemia and a high type 2 diabetes genetic risk score. A nationwide Korean cohort linked the triglyceride-glucose index (insulin resistance marker) to end-stage renal disease risk, especially with longer diabetes duration.
Research Themes
- Glycemia and cognitive outcomes in early type 2 diabetes
- Developmental programming: maternal hyperglycemia and genetic risk in youth
- Insulin resistance markers (TyG) predicting diabetic kidney disease progression
Selected Articles
1. Glucose-Lowering Medications, Glycemia, and Cognitive Outcomes: The GRADE Randomized Clinical Trial.
In 3721 adults with early T2D randomized to add glargine, glimepiride, liraglutide, or sitagliptin to metformin, there were no significant differences between drug classes in cognitive outcomes over a mean 4.1 years. However, higher time-weighted HbA1c was modestly associated with lower performance on multiple cognitive tests. Severe hypoglycemia requiring assistance was rare (0.9%).
Impact: This pragmatic RCT provides high-level evidence that drug class selection among common second-line agents does not differentially impact cognition in early T2D, while reinforcing the importance of overall glycemic control.
Clinical Implications: When choosing second-line therapy in early T2D, cognitive preservation should not drive drug class choice among these agents; instead, prioritize achieving and maintaining good glycemic control and minimizing hypoglycemia risk.
Key Findings
- No significant differences in cognitive outcomes across liraglutide, sitagliptin, glargine, or glimepiride added to metformin.
- Each 1-unit increase in time-weighted HbA1c associated with lower DSST (-0.94), lower immediate recall (-0.27), and lower category fluency (-0.28) scores.
- Severe hypoglycemia requiring assistance occurred in 0.9% across all groups.
Methodological Strengths
- Multicenter randomized design with large sample size and standardized cognitive assessments.
- Use of time-weighted HbA1c to model longitudinal glycemic exposure.
Limitations
- Duration (~4 years) may be insufficient to detect subtle, long-term cognitive effects of medications.
- Trial not specifically powered for between-class cognitive differences; practice effects and selection of relatively early T2D may attenuate signals.
Future Directions: Longer-term cognitive follow-up, trials targeting intensive glycemic control for cognitive preservation, and mechanistic studies (e.g., neuroimaging) across diverse populations and longer diabetes duration.
IMPORTANCE: Type 2 diabetes (T2D) is a risk factor for cognitive impairment. Whether the choice of the second-line glucose-lowering treatment added to metformin or glycemic control affects cognitive performance in T2D of relatively short duration (<10 years) is not known. OBJECTIVE: To compare the relative effect of 4 classes of glucose-lowering medications that were randomly added to metformin on cognitive performance and to examine the association of longitudinal glycemic levels with cognitive performance. DESIGN, SETTING, AND PARTICIPANTS: This randomized clinical trial (the GRADE study) was conducted at 36 clinical centers in the US and included 3721 participants with T2D with baseline and follow-up cognitive performance data. GRADE was implemented 2013 to 2021, and data for this study were analyzed from February 2024 to February 2025. INTERVENTIONS: For the primary objective, the exposure was randomization of metformin-treated participants to receive long-acting insulin (insulin glargine U-100), sulfonylurea (glimepiride), glucagon-like peptide-1 receptor agonist (liraglutide), or dipeptidyl peptidase-4 inhibitor (sitagliptin). The secondary objective assessed time-weighted hemoglobin A1c levels over the follow-up period. MAIN OUTCOMES AND MEASURES: The primary cognitive outcome was the Digit Symbol Substitution Test score; the secondary cognitive outcomes were the immediate and delayed recall in the Spanish English Verbal Learning Test and letter and category fluency test scores.
2. In Utero Exposure to Maternal Hyperglycemia and Offspring Type 2 Diabetes Genetic Risk Score Are Independently Associated With Risk of Impaired Glucose Tolerance in Youth.
Among 3,444 children aged 10–14 years, both higher maternal glycemia during pregnancy and a higher offspring T2D genetic risk score were independently associated with higher glucose levels. Youth exposed to gestational diabetes and with a T2D-GRS >75th percentile had a 15.9% prevalence of IGT/T2D vs 5.6% in nonexposed youth, indicating additive risk.
Impact: This study integrates prenatal metabolic exposure with polygenic risk, quantifying additive effects on youth dysglycemia—a key advance for precision prevention.
Clinical Implications: Children exposed to maternal hyperglycemia—especially those with high genetic risk—may warrant earlier screening and targeted lifestyle interventions to prevent progression to T2D.
Key Findings
- Higher maternal sum-of-glucose z scores and higher offspring T2D-GRS were each associated with higher child glucose levels.
- IGT + T2D prevalence was 15.9% in children with GDM exposure and T2D-GRS >75th percentile versus 5.6% in nonexposed children.
- Associations indicate additive—not substitutive—effects of genetic risk and in utero hyperglycemia on youth dysglycemia.
Methodological Strengths
- Use of a large pediatric cohort with standardized maternal OGTT metrics and well-defined outcomes at 10–14 years.
- Polygenic risk score constructed from 1,150 adult T2D-associated variants, enabling robust genetic stratification.
Limitations
- Observational design cannot infer causality; residual confounding is possible.
- Outcomes assessed at ages 10–14; longer-term trajectories into adulthood remain to be defined.
Future Directions: Test targeted prevention strategies in children with combined prenatal hyperglycemia exposure and high polygenic risk; replicate across ancestries and examine gene–environment interactions.
OBJECTIVE: We tested associations of type 2 diabetes genetic risk score (T2D-GRS) and exposure to maternal hyperglycemia with childhood impaired glucose tolerance (IGT) and T2D and glycemic outcomes in youth from the Hyperglycemia and Adverse Pregnancy Outcome Follow-Up Study. RESEARCH DESIGN AND METHODS: We calculated T2D-GRS using 1,150 known genetic variants associated with T2D in adults. In utero exposures included gestational diabetes mellitus (GDM) and sum-of-glucose z scores during oral glucose tolerance test at ∼28 weeks' gestation. IGT + T2D and continuous glycemic outcomes were measured when children were 10-14 years old. RESULTS: In 3,444 children (mean age, 11.4 years), higher maternal sum-of-glucose z scores and child T2D-GRS were both associated with higher glucose levels. In children exposed to GDM and with T2D-GRS >75th percentile, 15.9% had IGT + T2D, compared with 5.6% in nonexposed children. CONCLUSIONS: High genetic risk for diabetes and in utero exposure to maternal hyperglycemia are additively associated with IGT + T2D and glycemic outcomes in youth.
3. The Triglyceride-Glucose Index and Risk of End-Stage Renal Disease across Different Durations of Type 2 Diabetes Mellitus: A Longitudinal Cohort Study.
In a nationwide cohort of 1,219,148 adults with T2D (6.97 million person-years), higher TyG index quartiles were independently associated with greater ESRD risk, with stronger effects in longer diabetes duration. The highest TyG quartile had HR 1.592 vs lowest for ≥10 years’ duration, and a 10.239-fold higher HR compared to new-onset Q1 vs ≥10-year Q4 contrast.
Impact: This very large real-world analysis elevates the TyG index as a practical, scalable tool to stratify kidney failure risk in T2D, especially as disease duration lengthens.
Clinical Implications: Incorporate TyG into risk assessment—particularly in long-standing T2D—to identify patients needing intensified kidney-protective strategies (e.g., SGLT2 inhibitors, RAAS blockade, aggressive metabolic control) and closer monitoring.
Key Findings
- Across 1,219,148 adults with T2D, higher TyG quartiles independently predicted ESRD, with stronger associations in longer diabetes duration.
- Highest vs lowest TyG quartile HR for ESRD was 1.235 in new-onset T2D and 1.592 in ≥10-year duration.
- Compared to new-onset Q1, ≥10-year Q4 showed a 10.239-fold higher ESRD risk; associations were stronger in younger and comorbidity-free subgroups.
Methodological Strengths
- Nationwide cohort with over 6.9 million person-years and robust adjustment using Cox models.
- Stratification by diabetes duration and extensive subgroup analyses enhance clinical interpretability.
Limitations
- Observational design with potential residual confounding; TyG assessed at baseline may not reflect longitudinal changes.
- ESRD identified via administrative codes; generalizability beyond Korean population requires validation.
Future Directions: Prospective validation across diverse populations, integration of repeated TyG measures, and interventional studies targeting insulin resistance to reduce ESRD risk.
BACKGRUOUND: This study investigated the association between the triglyceride-glucose (TyG) index, a marker of insulin resistance, and the risk of end-stage renal disease (ESRD) in individuals with type 2 diabetes mellitus (T2DM), focusing on variations by diabetes duration. METHODS: We analyzed 1,219,148 Korean adults with T2DM from National Health Insurance Service data who underwent biennial health evaluations (2015 to 2016). ESRD was defined using specific procedural codes (V codes), and Cox proportional hazard models were employed to estimate hazard ratios (HRs) for ESRD across TyG index quartiles and diabetes duration categories, adjusting for various confounders. RESULTS: Over 6,967,381 person-years of follow-up, 7,548 participants developed ESRD. Higher TyG index quartiles were independently associated with increased risk of ESRD, which was more pronounced with longer diabetes duration. The adjusted HR for ESRD in the highest TyG quartile (Q4) compared to the lowest quartile (Q1) was 1.235 (95% confidence interval [CI], 0.995 to 1.533) in new-onset diabetes, and 1.592 (95% CI, 1.465 to 1.730) in those with diabetes for ≥10 years. Compared to the lowest TyG quartile in new-onset diabetes, the adjusted HR for ESRD in the highest quartile with diabetes duration ≥10 years increased to 10.239 (95% CI, 8.440 to 12.422). Subgroup analysis revealed that a higher TyG index consistently increased the risk of ESRD, with stronger associations observed in younger individuals and those without comorbidities. CONCLUSION: The TyG index is a significant predictor of ESRD in T2DM, particularly in those with prolonged diabetes duration. Targeting insulin resistance early may mitigate the risk of ESRD in this population.